A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Exclusion Criteria

• •Patient diagnosed with primary or secondary progressive MS.
• •Patient diagnosed with MS for more than 15 years duration with an EDSS score ≤2.0 at Screening.
• •Patient unable to complete or has a contraindication to an MRI
• •Patient with contraindications and/or severe hypersensitivity to corticosteroids including methylprednisolone or any of the excipients of study drug or etcs defined in the study protocol.
• •Patient who has currently or history of any of medical conditions described in the study protocol.
• •Patients who have received or going to receive any of prohibited medications or treatments defined in the study protocol.